BTK INHIBITORS
Clinical trials for BTK INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new BTK INHIBITORS trials appear
Sign up with your email to follow new studies for BTK INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to calm rogue immune cells in stubborn blood disorders
Disease control Not yet recruitingThis early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can better control immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) that haven't responded to other treatments. The drugs work together to stop the immune system from atta…
Matched conditions: BTK INHIBITORS
Phase: PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated May 26, 2026 07:16 UTC
-
Which blood cancer drug is safer for the heart?
Knowledge-focused Not yet recruitingThis study looks at whether the cancer drugs zanubrutinib or acalabrutinib are more likely to cause a heart rhythm problem called atrial fibrillation. Researchers will analyze health records from 15,000 adults with chronic B-cell cancers. The goal is to help doctors choose the sa…
Matched conditions: BTK INHIBITORS
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated May 18, 2026 12:09 UTC